Implementation of Trump's Drug-Pricing Orders Unlikely
We don't foresee any impact on pharma companies' moats or valuations.
President Donald Trump issued several orders on Nov. 20 designed to lower U.S. drug prices. We don’t expect implementation of these orders, however, given legal challenges, lack of support from the U.S. Congress and the incoming Biden administration, and unclear financial impacts. As a result, we don’t expect any major impact on the U.S. pricing power of drugs, a core pillar of our economic moat ratings and valuations in the drug industry.
One of the White House directives focused on pricing 50 of the largest Medicare B (hospital-administered) drugs at the lowest levels paid by developed countries. This would significantly affect U.S. prices, as we estimate drug pricing in the United States is close to double the prices in developed markets. However, we expect valid industry legal challenges to stop this order. The order doesn’t appear to have followed the normal legal process and instead was rushed out so Trump could enact the policy before leaving office. Additionally, we believe the rule is difficult to implement without legislative support from Congress. Further, we don’t expect the Biden administration to focus initially on U.S. drug pricing, especially in the form of these recent proposals, which lack full legal and congressional support.
Damien Conover does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.